Biochemical Validation of Self-Reported Smokeless Tobacco Abstinence among Smokeless Tobacco Users: Results from a Clinical Trial of Varenicline in India
- PMID: 26317285
- PMCID: PMC4698153
- DOI: 10.1080/02791072.2015.1073412
Biochemical Validation of Self-Reported Smokeless Tobacco Abstinence among Smokeless Tobacco Users: Results from a Clinical Trial of Varenicline in India
Abstract
The validity of self-reported tobacco use is often questioned given the potential for underestimation of use. This study used data from a double-blind, placebo-controlled clinical trial of varenicline for smokeless tobacco dependence in India to evaluate the accuracy of self-reported smokeless tobacco cessation using biochemical validation procedures and to evaluate correlates of reporting inaccuracy. Smokeless tobacco users attending a dental clinic at AIIMS were randomized to placebo or varenicline; all participants received counseling. Detailed smokeless tobacco use was recorded and abstinence was defined as cotinine-verified 7-day point prevalence cessation (cotinine < 50 ng/ml) and breath CO > 10 ppm at the end of 12 weeks of treatment. One-half of study completers (82/165) self-reported abstinence. Biochemical verification confirmed that (65.9%) subjects provided accurate self-reports while (34.1%) participants underreported tobacco use. These data indicate poor agreement between self-reported and biochemically confirmed abstinence (κ = -0.191). Underreporters of tobacco use had significantly higher baseline cotinine (p < 0.05), total craving (p < 0.012), and negative reinforcement craving (p < 0.001) vs. those whose self-reports were correctly verified. These findings provide evidence to support the need for biochemical validation of self-reported abstinence outcomes among smokeless tobacco users in cessation programs in India and identify high levels of pretreatment cotinine and craving levels as potential correlates of false reporting.
Keywords: biochemical validation; self-report; smokeless tobacco users; urine; varenicline.
Conflict of interest statement
Dr. Schnoll has served as a consultant to GlaxoSmithKline and Pfizer, and Pfizer provided the study medication and placebo for this study free of charge.
References
-
- Benowitz NL, Jacob P, Ahijevych K, Jarvis MJ, Hall S, LeHouezec J, Velicer W. Biochemical verification of tobacco use and cessation. Nicotine and Tobacco Research. 2002;4(2):149–159. - PubMed
-
- Boyd NR, Windsor RA, Perkins LL, Lowe JB. Quality of measurement of smoking status by self-report and saliva cotinine among pregnant women. Maternal Child Health Journal. 1998;2(2):77–83. Retrieved from link.springer.com/article/10.1023%2FA%3A1022936705438. - PubMed
-
- Dhavan P, Bassi S, Stigler MH, Arora M, Gupta VK, Perry CL, Reddy KS. Using Salivary Cotinine to Validate Self-Reports of Tobacco Use by Indian Youth Living in Low-Income Neighborhoods. Asian Pacific Journal of Cancer Prevention. 2011;12(10):2551–2554. Retrieved from europepmc.org/abstract/MED/22320954. - PMC - PubMed
-
- Dolcini MM, Adler NE, Ginsberg D. Factors influencing agreement between self-reports and biological measures of smoking among adolescents. Journal of Research on Adolescence. 1996;6(4):515–542. Retrieved from psycnet.apa.org/psycinfo/1997-02897-006.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources